{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:21:52Z","timestamp":1790655712580,"version":"4.1.0"},"reference-count":23,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"11","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Jacobio Pharmaceuticals Co., Ltd"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      Glecirasib, an inhibitor of Kirsten rat sarcoma viral oncogene homolog glycine\u2010to\u2010cysteine substitution at codon 12 (\n                      <jats:italic toggle=\"yes\">KRAS<\/jats:italic>\n                      G12C), has exhibited clinical activity in non\u2010small\u2010cell lung cancer (NSCLC) and colorectal cancer (CRC). Here, we investigated the efficacy and safety of glecirasib in patients with pancreatic ductal adenocarcinoma (PDAC) and other solid tumors (excluding NSCLC and CRC) that rarely harbor the\n                      <jats:italic toggle=\"yes\">KRAS<\/jats:italic>\n                      G12C mutation but for which effective treatment options remain limited.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      We conducted and analyzed two open\u2010label, phase I\/II trials in adult patients with\n                      <jats:italic toggle=\"yes\">KRAS<\/jats:italic>\n                      G12C mutant solid tumors, in which glecirasib was administered orally. The two trials had similar eligibility criteria and endpoints but differed in the regions of patient recruitment. We performed a pooled analysis of all patients, excluding NSCLC and CRC, from both trials. The primary endpoint in the pooled population was objective response rate (ORR). Efficacy and safety were assessed in patients who received at least one dose of glecirasib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">As of June 30, 2024, the pooled analysis included 54 patients who were treated with glecirasib: 32 PDACs, 8 biliary tract cancers (BTCs), 4 small intestinal cancers, 3 gastric cancers, 2 appendiceal cancers, and 5 other tumors. At baseline, 24 received \u2265 two prior lines of systemic therapy. Of the 53 efficacy\u2010evaluable patients, the confirmed ORR was 50.9% (95% confidence interval [CI], 36.8%\u201064.9%), with an ORR of 46.9% (95% CI, 29.1%\u201065.3%) in PDAC patients. Among other solid tumors, ORR was 71.4% (5\/7) in BTC, 100% (4\/4) in small intestinal cancer, and 66.7% (2\/3) in gastric cancer. Median progression\u2010free survival and median overall survival were 6.9 and 10.8 months, respectively, in the overall population, and 5.5 and 10.8 months, respectively, in patients with PDAC. Treatment\u2010related adverse events (TRAEs) of any grade occurred in 94.4% patients, with grade \u2265 3 TRAEs in 27.8%. No fatal TRAEs or TRAEs leading to treatment discontinuation occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">Glecirasib showed promising efficacy and was well tolerated in patients with PDAC and other advanced solid tumors (beyond NSCLC and CRC), warranting further expedited clinical development in this patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p xml:lang=\"en\">ClinicalTrials.gov identifier: NCT05009329 and NCT05002270.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cac2.70056","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T21:40:40Z","timestamp":1759441240000},"page":"1500-1512","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of glecirasib in solid tumors with\n                    <i>KRAS<\/i>\n                    G12C mutation: A pooled analysis of two phase I\/II trials"],"prefix":"10.34133","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-3255","authenticated-orcid":false,"given":"Jian","family":"Li","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing)","place":["Beijing, P. R. China"]},{"name":"Beijing Cancer Hospital","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Deng","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute & Hospital","place":["Tianjin, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Gu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-1947","authenticated-orcid":false,"given":"Antonio","family":"Calles Blanco","sequence":"additional","affiliation":[{"name":"Hospital General Universitario Gregorio Mara\u00f1on","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Li","sequence":"additional","affiliation":[{"name":"Sun Yat\u2010Sen Memorial Hospital","place":["Guangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Bai","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7078-7767","authenticated-orcid":false,"given":"Lin","family":"Wu","sequence":"additional","affiliation":[{"name":"Hunan Cancer Hospital","place":["Changsha, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[{"name":"Cancer Hospital Chinese Academy of Medical Sciences","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingya","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xi'an Jiaotong University","place":["Xi'an, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4817-7775","authenticated-orcid":false,"given":"Zhengbo","family":"Song","sequence":"additional","affiliation":[{"name":"Zhejiang Cancer Hospital","place":["Hangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Li","sequence":"additional","affiliation":[{"name":"Chongqing Cancer Hospital","place":["Chongqing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Liu","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University","place":["Jinan, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0528-9048","authenticated-orcid":false,"given":"Ligang","family":"Xing","sequence":"additional","affiliation":[{"name":"Shandong Cancer Hospital","place":["Jinan, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Wu","sequence":"additional","affiliation":[{"name":"Peking Union Medical College Hospital","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Mart\u00ednez\u2010P\u00e9rez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen del Rocio \u2013 PPDS","place":["Sevilla, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayala","family":"Hubert","sequence":"additional","affiliation":[{"name":"Hadassah\u2010Hebrew University Medical Center","place":["Jerusalem, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Zugazagoitia","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2167-8385","authenticated-orcid":false,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Fudan University Shanghai Cancer Center","place":["Shanghai, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Wang","sequence":"additional","affiliation":[{"name":"West China Hospital of Sichuan University","place":["Chengdu, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Henan Cancer Hospital","place":["Zhengzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilan","family":"Wen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanchang University","place":["Nanchang, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohao","family":"Xia","sequence":"additional","affiliation":[{"name":"Jiangsu Cancer Hospital","place":["Nanjing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diansheng","family":"Zhong","sequence":"additional","affiliation":[{"name":"Tianjin Medical University General Hospital","place":["Tianjin, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Chen","sequence":"additional","affiliation":[{"name":"Hangzhou Cancer Hospital","place":["Hangzhou, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuirong","family":"Jiang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Nanjing Medical University","place":["Nanjing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wang\u2010Gillam","sequence":"additional","affiliation":[{"name":"Jacobio (US) Pharmaceutical, Inc.","place":["Burlington, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuli","family":"Ding","sequence":"additional","affiliation":[{"name":"Jacobio Pharmaceuticals Co., Ltd.","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumei","family":"Liu","sequence":"additional","affiliation":[{"name":"Jacobio Pharmaceuticals Co., Ltd.","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyue","family":"Rao","sequence":"additional","affiliation":[{"name":"Jacobio Pharmaceuticals Co., Ltd.","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghu","family":"Liu","sequence":"additional","affiliation":[{"name":"Jacobio Pharmaceuticals Co., Ltd.","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing)","place":["Beijing, P. R. China"]},{"name":"Beijing Cancer Hospital","place":["Beijing, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12796"},{"issue":"1","key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41698-022-00334-z","article-title":"Comprehensive pan\u2010cancer genomic landscape of KRAS altered cancers and real\u2010world outcomes in solid tumors","volume":"6","author":"Lee JK","year":"2022","unstructured":"Lee JK, Sivakumar S, Schrock AB, Madison R, Fabrizio D, Gjoerup O, et\u00a0al. Comprehensive pan\u2010cancer genomic landscape of KRAS altered cancers and real\u2010world outcomes in solid tumors. NPJ Precis Oncol. 2022;6((1)):91.","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMc2030638","article-title":"Distribution of KRAS (G12C) Somatic Mutations across Race, Sex, and Cancer Type","volume":"384","author":"Nassar AH","year":"2021","unstructured":"Nassar AH, Adib E, Kwiatkowski DJ. Distribution of KRAS (G12C) Somatic Mutations across Race, Sex, and Cancer Type. N Engl J Med. 2021;384((2)):185\u20137.","journal-title":"N Engl J Med"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00547","article-title":"Identification of KRAS(G12C) Mutations in Circulating Tumor DNA in Patients With Cancer","volume":"6","author":"Thein KZ","year":"2022","unstructured":"Thein KZ, Biter AB, Banks KC, Duda AW, Saam J, Roszik J, et\u00a0al. Identification of KRAS(G12C) Mutations in Circulating Tumor DNA in Patients With Cancer. JCO Precis Oncol. 2022;6:e2100547.","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1252516","article-title":"Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer","volume":"13","author":"Qunaj L","year":"2023","unstructured":"Qunaj L, May MS, Neugut AI, Herzberg BO. Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer. Front Oncol. 2023;13:1252516.","journal-title":"Front Oncol"},{"key":"e_1_3_2_7_2","unstructured":"SEER*Explorer; Surveillance Research Program; Apr 17 2024. Data source(s): SEER Incidence Data November 2023 Submission (1975\u20102021) SEER 22 registries. US National Cancer Institute. 2025. Available from: https:\/\/seer.cancer.gov\/statistics\u2010network\/explorer\/"},{"key":"e_1_3_2_8_2","unstructured":"Ferlay JEM Lam F Laversanne M Colombet M Mery L et\u00a0al. Global Cancer Observatory: Cancer Today. Lyon France: International Agency for Research on Cancer 2024. [cited Jan 06 2025]. Available from: https:\/\/gco.iarc.who.int\/today"},{"issue":"3","key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1053\/j.gastro.2023.05.043","article-title":"Incidence, Risk Factors, and Temporal Trends of Small Intestinal Cancer: A Global Analysis of Cancer Registries","volume":"165","author":"Huang J","year":"2023","unstructured":"Huang J, Chan SC, Fung YC, Mak FY, Lok V, Zhang L, et\u00a0al. Incidence, Risk Factors, and Temporal Trends of Small Intestinal Cancer: A Global Analysis of Cancer Registries. Gastroenterology. 2023;165((3)):600\u201312.","journal-title":"Gastroenterology"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1200\/EDBK_160831","article-title":"Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling","volume":"35","author":"Bridgewater JA","year":"2016","unstructured":"Bridgewater JA, Goodman KA, Kalyan A, Mulcahy MF. Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling. Am Soc Clin Oncol Educ Book. 2016;35:e194\u2013203.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-020-00199-z","article-title":"Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non\u2010small cell lung cancer patients","volume":"8","author":"Liu SY","year":"2020","unstructured":"Liu SY, Sun H, Zhou JY, Jie GL, Xie Z, Shao Y, et\u00a0al. Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non\u2010small cell lung cancer patients. Biomark Res. 2020;8:22.","journal-title":"Biomark Res"},{"issue":"15","key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.ejca.2010.05.022","article-title":"Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta\u2010analysis of 22 studies","volume":"46","author":"Qiu LX","year":"2010","unstructured":"Qiu LX, Mao C, Zhang J, Zhu XD, Liao RY, Xue K, et\u00a0al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta\u2010analysis of 22 studies. Eur J Cancer. 2010;46((15)):2781\u20137.","journal-title":"Eur J Cancer"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","DOI":"10.1177\/11795549251331759","article-title":"Potency and Safety of KRAS G12C Inhibitors in Solid Tumors: A Systematic Review","volume":"19","author":"El Zaitouni S","year":"2025","unstructured":"El Zaitouni S, Laraqui A, Boustany Y, Benmokhtar S, El Annaz H, Abi R, et\u00a0al. Potency and Safety of KRAS G12C Inhibitors in Solid Tumors: A Systematic Review. Clin Med Insights Oncol. 2025;19:11795549251331759.","journal-title":"Clin Med Insights Oncol"},{"issue":"4","key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00262-024-03632-6","article-title":"Clinical immunotherapy in pancreatic cancer","volume":"73","author":"Ye X","year":"2024","unstructured":"Ye X, Yu Y, Zheng X, Ma H. Clinical immunotherapy in pancreatic cancer. Cancer Immunol Immunother. 2024;73((4)):64.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C\u2010Mutated Advanced Pancreatic Cancer","volume":"388","author":"Strickler JH","year":"2023","unstructured":"Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido\u2010Laguna I, et\u00a0al. Sotorasib in KRAS p.G12C\u2010Mutated Advanced Pancreatic Cancer. N Engl J Med. 2023;388((1)):33\u201343.","journal-title":"N Engl J Med"},{"issue":"25","key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation","volume":"41","author":"Bekaii\u2010Saab TS","year":"2023","unstructured":"Bekaii\u2010Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, et\u00a0al. Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation. J Clin Oncol. 2023;41((25)):4097\u2013106.","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303810"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c02313"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03401-z"},{"issue":"16","key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2024.42.16_suppl.3008","article-title":"Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB\u201021822) and SHP2 inhibitor (JAB\u20103312) in patients with KRAS p.G12C mutated solid tumors","volume":"42","author":"Zhao J","year":"2024","unstructured":"Zhao J, Fang J, Yu Y, Chu Q, Li X, Chen J, et\u00a0al. Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB\u201021822) and SHP2 inhibitor (JAB\u20103312) in patients with KRAS p.G12C mutated solid tumors. J Clin Oncol logo. 2024;42((16)_suppl):3008.","journal-title":"J Clin Oncol logo"},{"issue":"4","key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2025.43.4_suppl.191","article-title":"Efficacy and safety of glecirasib (JAB\u201021822) monotherapy and in combination with cetuximab in patients with KRAS G12C\u2010mutated advanced colorectal cancer","volume":"43","author":"Li J","year":"2025","unstructured":"Li J, Huang J, Ba Y, Cao B, Luo S, Li W, et\u00a0al. Efficacy and safety of glecirasib (JAB\u201021822) monotherapy and in combination with cetuximab in patients with KRAS G12C\u2010mutated advanced colorectal cancer. J Clin Oncol logo. 2025;43((4)_suppl):191.","journal-title":"J Clin Oncol logo"},{"issue":"3","key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1200\/JCO.2024.42.3_suppl.604","article-title":"Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB\u201021822) in patients with pancreatic cancer and other solid tumors","volume":"42","author":"Li J","year":"2024","unstructured":"Li J, Shen L, Gu Y, Calles A, Wu L, Ba Y, et\u00a0al. Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB\u201021822) in patients with pancreatic cancer and other solid tumors. J Clin Oncol logo. 2024;42((3)_suppl):604.","journal-title":"J Clin Oncol logo"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI\u20101 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long\u2010term survivors","volume":"108","author":"Wang\u2010Gillam A","year":"2019","unstructured":"Wang\u2010Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, et\u00a0al. NAPOLI\u20101 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long\u2010term survivors. Eur J Cancer. 2019;108:78\u201387.","journal-title":"Eur J Cancer"},{"issue":"1","key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-024-01948-4","article-title":"Irinotecan hydrochloride liposome HR070803 in combination with 5\u2010fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine\u2010based therapy (PAN\u2010HEROIC\u20101): a phase 3 trial","volume":"9","author":"Cui J","year":"2024","unstructured":"Cui J, Qin S, Zhou Y, Zhang S, Sun X, Zhang M, et\u00a0al. Irinotecan hydrochloride liposome HR070803 in combination with 5\u2010fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine\u2010based therapy (PAN\u2010HEROIC\u20101): a phase 3 trial. Signal Transduct Target Ther. 2024;9((1)):248.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1002\/cac2.70056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:47:57Z","timestamp":1773823677000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1002\/cac2.70056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/cac2.70056"],"URL":"https:\/\/doi.org\/10.1002\/cac2.70056","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"2025-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}